Footnotes:a = Died of
pneumothorax followed by spontaneous rupture of
bulla induced by previous
interstitial pneumonitis 14 months after discontinuation of bicalutamide and recovery from interstitial pneumonitis. Notes: Twelve additional cases of bicalutamide-associated interstitial pneumonitis, three of which resulted in death, were observed in an 87,000-patient cohort from
MedWatch (
U.S.Tooltip United States
FDATooltip Food and Drug Administration passive adverse-event reporting database) between 1998 and 2000 (0.01% incidence).[19][20][21] The median age of the patients was 73.5 years (range 59 to 91 years), and median duration of bicalutamide exposure was 7.5 weeks (range 1 to 312 weeks).[19] Cases of interstitial pneumonitis have also been reported in association with
flutamide,
nilutamide, and
gonadotropin-releasing hormone (GnRH) agonists.[8][19]
^Wong PW, Macris N, DiFabrizio L, Seriff NS (February 1998). "Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature". Chest. 113 (2): 548–50.
doi:
10.1378/chest.113.2.548.
PMID9498983.
^McCaffrey JA, Scher HI (July 1998). "Interstitial pneumonitis following bicalutamide treatment for prostate cancer". J. Urol. 160 (1): 131.
doi:
10.1016/S0022-5347(01)63059-3.
PMID9628626.
^McLeod DG (1997). "Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer". Oncologist. 2 (1): 18–27.
PMID10388026. Interstitial pneumonitis in patients treated with nilutamide is well-documented in the literature [81-85], and one case has been reported in a patient treated with high-dose (200 mg) bicalutamide in a clinical trial (H. Scher, personal communication).
^Shioi K, Yoshida M, Sakai N (November 2003). "Interstitial pneumonitis induced by bicalutamide and leuprorelin acetate for prostate cancer". Int. J. Urol. 10 (11): 625–6.
doi:
10.1046/j.1442-2042.2003.00705.x.
PMID14633092.
^Molina Mancero G, Picón X, Di Tullio F, Ernst G, Dezanzo P, Salvado A, Chertcoff JF (October 2016). "Neumonía intersticial inducida por bloqueo androgénico máximo como tratamiento de cáncer de próstata avanzado" [Fatal interstitial lung disease associated with maximum androgen blockade]. Rev Med Chil (in Spanish). 144 (10): 1356–1359.
doi:
10.4067/S0034-98872016001000017.
PMID28074993.
^Smith TJ, Antonarakis ES (July 2020). "Recovery From Bicalutamide-Associated Pneumonitis in a Patient With ATM-Deficient Prostate Cancer". JCO Oncol Pract: OP2000219.
doi:
10.1200/OP.20.00219.
PMID32716759.
^
abcBennett CL, Raisch DW, Sartor O (October 2002). "Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect". Ann. Intern. Med. 137 (7): 625.
doi:
10.7326/0003-4819-137-7-200210010-00029.
PMID12353966.
^"Pneumonitis and non steroidal antiandrogens". Prescrire Int. 12 (66): 141. August 2003.
PMID12908492.
Footnotes:a = Died of
pneumothorax followed by spontaneous rupture of
bulla induced by previous
interstitial pneumonitis 14 months after discontinuation of bicalutamide and recovery from interstitial pneumonitis. Notes: Twelve additional cases of bicalutamide-associated interstitial pneumonitis, three of which resulted in death, were observed in an 87,000-patient cohort from
MedWatch (
U.S.Tooltip United States
FDATooltip Food and Drug Administration passive adverse-event reporting database) between 1998 and 2000 (0.01% incidence).[19][20][21] The median age of the patients was 73.5 years (range 59 to 91 years), and median duration of bicalutamide exposure was 7.5 weeks (range 1 to 312 weeks).[19] Cases of interstitial pneumonitis have also been reported in association with
flutamide,
nilutamide, and
gonadotropin-releasing hormone (GnRH) agonists.[8][19]
^Wong PW, Macris N, DiFabrizio L, Seriff NS (February 1998). "Eosinophilic lung disease induced by bicalutamide: a case report and review of the medical literature". Chest. 113 (2): 548–50.
doi:
10.1378/chest.113.2.548.
PMID9498983.
^McCaffrey JA, Scher HI (July 1998). "Interstitial pneumonitis following bicalutamide treatment for prostate cancer". J. Urol. 160 (1): 131.
doi:
10.1016/S0022-5347(01)63059-3.
PMID9628626.
^McLeod DG (1997). "Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer". Oncologist. 2 (1): 18–27.
PMID10388026. Interstitial pneumonitis in patients treated with nilutamide is well-documented in the literature [81-85], and one case has been reported in a patient treated with high-dose (200 mg) bicalutamide in a clinical trial (H. Scher, personal communication).
^Shioi K, Yoshida M, Sakai N (November 2003). "Interstitial pneumonitis induced by bicalutamide and leuprorelin acetate for prostate cancer". Int. J. Urol. 10 (11): 625–6.
doi:
10.1046/j.1442-2042.2003.00705.x.
PMID14633092.
^Molina Mancero G, Picón X, Di Tullio F, Ernst G, Dezanzo P, Salvado A, Chertcoff JF (October 2016). "Neumonía intersticial inducida por bloqueo androgénico máximo como tratamiento de cáncer de próstata avanzado" [Fatal interstitial lung disease associated with maximum androgen blockade]. Rev Med Chil (in Spanish). 144 (10): 1356–1359.
doi:
10.4067/S0034-98872016001000017.
PMID28074993.
^Smith TJ, Antonarakis ES (July 2020). "Recovery From Bicalutamide-Associated Pneumonitis in a Patient With ATM-Deficient Prostate Cancer". JCO Oncol Pract: OP2000219.
doi:
10.1200/OP.20.00219.
PMID32716759.
^
abcBennett CL, Raisch DW, Sartor O (October 2002). "Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect". Ann. Intern. Med. 137 (7): 625.
doi:
10.7326/0003-4819-137-7-200210010-00029.
PMID12353966.
^"Pneumonitis and non steroidal antiandrogens". Prescrire Int. 12 (66): 141. August 2003.
PMID12908492.